Efficacy of chlorophyll c2 for seasonal allergic rhinitis: single-center double-blind randomized control trial
Chlorophyll c2 extracted from Sargassum horneri improved allergic symptoms in an animal model of allergic rhinitis. In the present study, we explored the efficacy of chlorophyll c2 in patients with seasonal allergic rhinitis. This was a single-center, randomized, double-blind placebo-controlled trial. Sixty-six patients aged 20–43 years, each with a 2-year history of seasonal allergic rhinitis, were randomly assigned to receive either a single daily dose (0.7 mg) of chlorophyll c2 or placebo for 12 weeks. The use of medications including H1-antihistamines and topical nasal steroids was recorded by rescue medication scores (RMSs) noted after 4, 8, and 12 weeks of treatment. Disease-specific quality of life was measured using the Japan Rhinitis Quality of Life Questionnaire (JRQLQ) both before and after 4, 8, and 12 weeks of treatment. The RMS at 8 weeks was significantly better in the chlorophyll c2 than the placebo group (mean RMS difference = −3.09; 95 % confidence interval = −5.96 to −0.22); the mean RMS at 4 weeks was only slightly better in the chlorophyll c2 group. The JRQLQ scores did not differ significantly between the two groups. Chlorophyll c2 would have a potential to be an alternative treatment for allergic rhinitis.
KeywordsComplementary therapies Chlorophyll c2 Sargassum horneri Seaweed Allergic rhinitis
Compliance with ethical standards
The Maruha Nichiro Corporation sponsored these trials and prepared the chlorophyll c2 and placebo capsules. The Maruha Nichiro Corporation did not have any role in the study design, data analysis, interpretation, or reporting of results.
Conflict of interest
TF declares that he has no conflict of interest. NN declares that he has no conflict of interest. JN declares that he has no conflict of interest. TT declares that he has no conflict of interest. KA declares that he has no conflict of interest. HT declares that he has no conflict of interest. TS collaborated with the Maruha Nichiro Corporation and reported some basic researches (reference No. 9 and No. 10). NH declares that he has no conflict of interest.
Research involving human participants
All procedures performed in studies involving human participants were in accordance with the guidance of clinical research by Japan Ministry of Health Labour and Welfare and with the 1964 Helsinki declaration and its later amendment ethical standards.
Written informed was obtained from all individual participants included in this study before trial enrollment.
- 3.Committee of Practice Guidance for management of Allergic Rhinitis (2016) Practice Guideline for the Management of Allergic Rhinitis in Japan, 8th edition [in Japanese]. Life Sci, TokyoGoogle Scholar
- 5.Cheng J, Yang XN, Liu X, Zhang SP (2006) Capsaicin for allergic rhinitis in adults. Cochrane Database Syst Rev:CD004460Google Scholar